<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04767529</url>
  </required_header>
  <id_info>
    <org_study_id>AK-US-001-0102</org_study_id>
    <nct_id>NCT04767529</nct_id>
  </id_info>
  <brief_title>A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <acronym>Harmony</acronym>
  <official_title>A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akero Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akero Therapeutics, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind,&#xD;
      placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in liver fibrosis with no worsening steatohepatitis assessed by NASH CRN system</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of steatohepatitis with no worsening of fibrosis assessed by the NASH CRN system</measure>
    <time_frame>24 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver fibrosis with no worsening of steatohepatitis assessed by the NASH CRN system</measure>
    <time_frame>96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder based on NASH CRN: patients who had a decrease of ≥ one point in fibrosis score</measure>
    <time_frame>24 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hepatic fat fraction</measure>
    <time_frame>24 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of lipoproteins - Non-HDL-C, HDL-C, and LDL-C</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of markers of glycemic control - HbA1c</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of markers of glycemic control - C-Peptide</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of markers of glycemic control - Adiponectin</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of markers of glycemic control - HOMA-IR</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of non-invasive fibrosis biomarkers - ELF</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of non-invasive fibrosis biomarkers - Pro-C3</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of non-invasive fibrosis biomarkers - NIS-4</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of non-invasive fibrosis biomarkers - liver stiffness assessed by transient elastography (FibroScan®)</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of body weight</measure>
    <time_frame>24 Weeks, 48 Weeks, 96 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>EFX 28 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EFX 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFX</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>EFX 28 mg</arm_group_label>
    <arm_group_label>EFX 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and non-pregnant, non-lactating females between 18 - 75 years of age inclusive,&#xD;
             based on the date of the screening visit.&#xD;
&#xD;
          -  Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity,&#xD;
             dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes.&#xD;
&#xD;
          -  FibroScan® measurement &gt; 8.5 kPa.&#xD;
&#xD;
          -  Biopsy-proven NASH. Must have had a liver biopsy obtained ≤ 180 days prior to&#xD;
             randomization with fibrosis stage 2 to 3 and a non-alcoholic fatty liver disease&#xD;
             (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the&#xD;
             following NAS components:&#xD;
&#xD;
               -  Steatosis (scored 0 to 3),&#xD;
&#xD;
               -  Ballooning degeneration (scored 0 to 2), and&#xD;
&#xD;
               -  Lobular inflammation (scored 0 to 3).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight loss &gt; 5% in the 3 months prior to screening until randomization or from the&#xD;
             time of the diagnostic liver biopsy until randomization, whichever is longer.&#xD;
&#xD;
          -  Presence of cirrhosis on liver biopsy (stage 4 fibrosis).&#xD;
&#xD;
          -  Type 1 or uncontrolled Type 2 diabetes.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akero Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Study Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akero Study Director</last_name>
    <phone>650-487-6488</phone>
    <email>HarmonyStudies@akerotx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 106</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 104</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 210</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 144</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 214</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 129</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 109</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Akero Site 122</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 101</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Akero Site 113</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 112</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92866</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 143</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92866</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Akero Site 139</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 206</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 134</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 135</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 203</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 138</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 110</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 146</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 127</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>94240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 218</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 111</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 136</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 209</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 102</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 119</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 107</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 118</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 142</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Akero Site 121</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 128</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 108</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 131</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 123</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 130</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 126</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 114</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 212</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 125</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 213</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 117</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 205</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 211</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 140</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 124</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 116</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 103</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 202</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 141</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 204</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 133</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 120</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Akero Site 115</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>San Juan</city>
        <zip>927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 215</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

